Cargando…

Resource utilization, costs and treatment patterns of switching and discontinuing treatment of MS patients with high relapse activity

BACKGROUND: Multiple sclerosis (MS) is a chronic disease that affects mainly adults in the prime of their lives. However, few studies report the impact of high annual relapse rates on outcomes. The purpose of this study was to identify high relapse activity (HRA) in patients with MS, comparing diffe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raimundo, Karina, Tian, Haijun, Zhou, Huanxue, Zhang, Xin, Kahler, Kristijan H, Agashivala, Neetu, Kim, Edward
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626727/ https://www.ncbi.nlm.nih.gov/pubmed/23565628 http://dx.doi.org/10.1186/1472-6963-13-131

Ejemplares similares

Treatment selection and experience in multiple sclerosis: survey of neurologists
por: Hanson, Kristin A, et al.
Publicado: (2014)

Economic Burden Associated with Extrapyramidal Symptoms in a Medicaid Population with Schizophrenia
por: Abouzaid, Safiya, et al.
Publicado: (2012)

Costs and health care resource utilization among chronic obstructive pulmonary disease patients with newly acquired pneumonia
por: Lin, Junji, et al.
Publicado: (2014)

Group-based trajectory modeling to assess adherence to biologics among patients with psoriasis
por: Li, Yunfeng, et al.
Publicado: (2014)

Annual Cost Burden by Level of Relapse Severity in Patients with Multiple Sclerosis
por: Nicholas, Jacqueline, et al.
Publicado: (2020)

Impact of the COVID-19 pandemic on healthcare resource utilization across selected disease areas in the USA
por: Engelbrecht, Kayla, et al.
Publicado: (2022)

Relapse Rates in Patients with Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims Database Study
por: Bergvall, Niklas, et al.
Publicado: (2014)

Patient perspectives on switching disease-modifying therapies in the NARCOMS registry
por: Salter, Amber R, et al.
Publicado: (2014)

Impact of discontinuity in health insurance on resource utilization
por: Banerjee, Ritesh, et al.
Publicado: (2010)

Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial
por: Calkwood, Jonathan, et al.
Publicado: (2014)

Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis
por: Yu, Justin S, et al.
Publicado: (2021)

Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study
por: Agashivala, Neetu, et al.
Publicado: (2013)

Evaluating Treatment Patterns, Relapses, Healthcare Resource Utilization, and Costs Associated with Disease-Modifying Treatments for Multiple Sclerosis in DMT-Naïve Patients
por: Freeman, Leorah, et al.
Publicado: (2021)

A cross-sectional survey of patient satisfaction and subjective experiences of treatment with fingolimod
por: Hanson, Kristin A, et al.
Publicado: (2013)

Predictors of relapse after discontinuing systemic treatment in autoimmune chronic uveitis
por: Simonini, Gabriele, et al.
Publicado: (2014)

The cost of relapse and the predictors of relapse in the treatment of schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2010)

Time to Relapse After Discontinuing Systemic Treatment for Psoriasis: A Systematic Review
por: Masson Regnault, Marie, et al.
Publicado: (2022)

Resource Use and Costs in an Insured Population of Patients with Chronic Idiopathic/Spontaneous Urticaria
por: Broder, Michael S., et al.
Publicado: (2015)

Healthcare Costs and Resource Utilization in Patients with Multiple Sclerosis Relapses Treated with H.P. Acthar Gel(®)
por: Gold, Laura S., et al.
Publicado: (2016)

Clinical events preceding switching and discontinuation of oral anticoagulant treatment in patients with atrial fibrillation
por: Hellfritzsch, Maja, et al.
Publicado: (2017)

Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network
por: Hillert, Jan, et al.
Publicado: (2021)

Impact of antiepileptic-drug treatment burden on health-care-resource utilization and costs
por: Rajagopalan, Krithika, et al.
Publicado: (2018)

Microscopic polyangiitis after alemtuzumab treatment in relapsing-remitting MS
por: Sauer, Eva-Maria, et al.
Publicado: (2018)

Switching to second line MS disease-modifying therapies is associated with decreased relapse rate
por: Marriott, James John, et al.
Publicado: (2023)

Cost-utility analysis of treatment options after initial tumor necrosis factor inhibitor therapy discontinuation in patients with rheumatoid arthritis
por: Karpes Matusevich, Aliza R, et al.
Publicado: (2021)

Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers
por: Lo Re, Marianna, et al.
Publicado: (2015)

Switching treatments in COPD: implications for costs and treatment adherence
por: Braido, Fulvio, et al.
Publicado: (2015)

Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation
por: Correll, Christoph U, et al.
Publicado: (2019)

Cost Effectiveness Analysis of Avonex and CinnoVex in Relapsing Remitting MS
por: Najafi, Behzad, et al.
Publicado: (2015)

Abstract: Treatment of Craniosynostosis: The Impact of Hospital Surgical Volume on Cost, Resource Utilization, and Outcomes
por: Bucknor, Alexandra, et al.
Publicado: (2017)

Treatment Patterns, Health Care Resource Utilization, and Cost in Patients with Myelofibrosis in the United States
por: Copher, Ronda, et al.
Publicado: (2022)

Hypoglycemia After Initiation of Basal Insulin in Patients with Type 2 Diabetes in the United States: Implications for Treatment Discontinuation and Healthcare Costs and Utilization
por: Dalal, Mehul R., et al.
Publicado: (2017)

Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis
por: Burks, Jack, et al.
Publicado: (2017)

Patient Characteristics, Health Care Resource Utilization, and Costs Associated with Treatment-Regimen Failure with Biologics in the Treatment of Psoriasis
por: A. Foster, Shonda, et al.
Publicado: (2016)

Lymphocyte recovery after fingolimod discontinuation in patients with MS
por: Nagy, Sara, et al.
Publicado: (2020)

Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia
por: Wilson, Michele, et al.
Publicado: (2016)

Association Between Switching to a High-Deductible Health Plan and Discontinuation of Type 2 Diabetes Treatment
por: Fendrick, A. Mark, et al.
Publicado: (2019)

Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis
por: Yawn, Barbara P, et al.
Publicado: (2013)

Difference-in-Differences Method in Comparative Effectiveness Research: Utility with Unbalanced Groups
por: Zhou, Huanxue, et al.
Publicado: (2016)

Discontinuing psychotropic drug treatment
por: Tondo, Leonardo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5rf06dv694i85c6knat59cr3ue